← All trials
NCT05636111
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Jul 31, 2026
- First posted
- Dec 5, 2022
- Last posted
- Dec 5, 2022
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- Jazz PharmaceuticalsCollaborator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.